2309 results about "Diketone" patented technology

As a novel substance having a novel skeleton, an organometallic complex with high emission efficiency which achieves improved color purity by a reduction of half width of an emission spectrum is provided. One embodiment of the present invention is an organometallic complex in which a β-diketone and a six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom are ligands. In General Formula (G1), X represents a substituted or unsubstituted six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom. Further, R¹ to R⁴ each represent a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms.

A method of forming a single-metal film on a substrate by plasma ALD includes: contacting a surface of a substrate with a β-diketone metal complex in a gas phase; exposing molecule-attached surface to a nitrogen-hydrogen mixed plasma; and repeating the above steps, thereby accumulating atomic layers to form a single-metal film on the substrate.

Metal-oxide films for lithographic applications are provided. The films are formed from compositions comprising metal-oxide precursor compounds including metals and metalloids other than silicon. These films are easily produced and can be modified with a variety of ligands, including alkoxides, phenoxides, carboxylates, beta-diketones, and beta-ketoesters.

Benzodiazepinc compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of structures (I) or (II): wherein R₁, R₂, R₃ and R₄ are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drugs screening assays and other diagnostic methods.

Self-photo-initiating liquid oligomeric compositions are disclosed. The oligomeric compositions are formed from multifunctional mercaptans and Michael addition polyacrylate resins, synthesized from multifunctional acrylates and β-dicarbonyl Michael donors, specifically β-keto esters, β-diketones, β-ketoamides or β-ketoanilides or combinations thereof The oligomeric compositions are provided along with uses thereof and methods of fabricating.

A coating composition is provided comprising a) an aqueous dispersion, having a pH of less than 7.5, of silica nanoparticles having average particle diameters of 40 nanometers or less, b) an alkoxysilane oligomer; c) a silane coupling agent, and d) optionally a metal β-diketone complexing agent. The compositions may be used to prepare coated articles wherein the coating is substantially uniform in thickness, durably adheres to the substrate, and provides hydrophilic and/or antireflection surface properties to the substrate.

The invention discloses a powdery calcium-zinc complex heat stabilizer, which comprises the following components in weight ratio: 20-30 parts of zinc stearate, 15-25 parts of calcium stearate, 4-8 parts of epoxy compound, 15-25 parts of beta-diketone, 2-6 parts of antioxidant, 10-15 parts of polyatomic alcohol, 12-16 parts of inorganic assistant and 10-15 parts of lubricant. The powdery calcium-zinc complex heat stabilizer disclosed by the invention is capable of effectively delaying the generation of zinc-burning phenomenon of a system and improving the initial-stage and long-term heat stability of polyvinyl chloride (PVC), and moreover, the system has a good lubrication component, thus, the dispersion property and the processing property of the system in resin can be improved, thereby being beneficial to reducing energy consumption.

This disclosure relates to amides, aryl sulphonamides, aryl ureas, and α,β-diketones derivatives useful as carboxylesterase esterase inhibitors. The disclosure is also directed to the use of these compounds as selective human intestinal carboxylesterase inhibitors and insect carboxylesterase inhibitors. The disclosure is also directed to pharmaceutical compositions and pesticide formulations containing these compounds, and to methods for treating or ameliorating the toxic effects following administration of drugs such as cancer therapy drugs, treating or ameliorating the effects of a drug overdose, and to the use of the compounds for increasing the effectiveness of insecticides and pesticides.

The invention provides a completely new process route for synthesizing dexamethasone and series products thereof. The invention adopts 1, 4, 9, 16-tetraene-pregna-3, 20-diketone as the original material which is modified by 9, 11bits, 16, 17 bits and 21 bits so as to obtain the dexamethasone and the series products thereof such as dexamethasone acetate and dexamethasone sodium phosphate and the like. The process has the advantage that the invention adopts the existing intermediates of manufacturers as the original material; the route is simple; the materials are available; the use of expensive accessories is avoided; the yield and the cost are dramatically better than that of the prior methods used for synthesizing the dexamethasone and derivatives thereof; moreover, the adoption of the existing intermediates realizes the combined-line prodction of the betamethasone series products and the dexamethasone series products, thus greatly reducing the manufacturing cost and the industrial manufacturing condition.

A resist composition is provided comprising a (co)polymer comprising recurring units of acid labile group-substituted (meth)acrylic acid, styrenecarboxylic acid or vinylnaphthalenecarboxylic acid and/or recurring units having an acid labile group-substituted phenolic hydroxyl group, an acid generator, and a metal salt of carboxylic acid or a metal complex of β-diketone. Due to a high contrast of alkaline dissolution rate before and after exposure, high resolution, high sensitivity, and controlled acid diffusion rate, the composition forms a pattern with satisfactory profile and minimal LER.

The invention discloses an iridium complex phosphor material taking a phthalazine derivative as a ligand. The structure of the material is shown as formulas (I) and (II), wherein Ar represents aryl, substituted aryl, heterocycle aryl and substituted heterocycle aryl; R can be one of a halogen atom, alkyl, substituted alkyl, alkoxyl, aryloxy, an alkylthio group, arylthio, aromatic amino, aliphatic amino or a heterocyclic substituent; L^Y can be one of N-COOH, 8-hydroxyquinoline, beta-diketone, N^NH and the like; N^N can be bipyridyl, diquinoline, 1,10-phenanthroline, a derivative of the 1,10-phenanthroline and the like; and Z can be hexafluorophosphate and perchlorate. A dicyclic or ionic iridium complex phosphorescent electroluminescent device taking the phthalazine derivative as the ligand obtained with the preparation method has high internal and external quantum yields, high luminance and high stability. A dicyclic iridium complex is shown as a formula (I), i.e., (C^N)2Ir(L^Y); and an ionic iridium complex is shown as a formula (II), i.e., (C^N)2Ir(N^N)<+>Z<->.

A method for depositing a thin ruthenium (Ru) film on a substrate in a reaction chamber, comprising: step (i) of supplying at least one type of gas of a ruthenium precursor being a β-diketone-coordinated ruthenium complex and causing the gas to be adsorbed to the substrate in the reaction chamber; step (ii) of supplying a reducing gas into the reaction chamber and exciting the reducing gas, or supplying an excited reducing gas into the reaction chamber, in order to activate the ruthenium precursor adsorbed to the substrate; and step (iii) of repeating steps (i) and (ii) to form a thin ruthenium film on the substrate.

The invention discloses a composition containing HFC-161 and a stabilizer, wherein the stabilizer is selected from one or more of epoxy compound, nitro-compound, hindered amines, hindered phenols, secondary arylamines, beta-diketones, phosphite esters, salicylic acid esters, cinnamic acid esters, hydroxybenzophenones, hydroxybenzoic acids, hydroxylphenyl benzotriazoles, hydroxylphenyl triazines, oxanilides, formamidines, polyhydric alcohols, ortho-formates, organosulfur compounds, olefins, ethanol amines and fatty amines. The composition provided by the invention is capable of keeping a stable state in a long time under the coexistence of air or oxygen, and capable of being used as a heat transfer composition in the form of a liquid or a gas, a refrigerant, an aerosol propellant and the like.

The present invention provides atomic layer deposition systems and methods that include metal compounds with at least one β-diketiminate ligand. Such systems and methods can be useful for depositing metal-containing layers on substrates.

The invention discloses a type of amino acid modified curcumin, a synthesis method thereof, and an application thereof. According to the invention, structural modification is carried out upon curcumin by using natural amino acid, such that 1-(4-hydroxy-3-methoxyphenyl)-7-(4-oxyacetyl amino carbobenzoxy-3-methoxyphenyl)-1,6-heptadiene-3,5-diketone which is represented by a general formula (I) is obtained. With an MTT method, evaluation is carried out upon the compound represented by the general formula (I) in the inhabitance of proliferation activities of four cells which are K562, H22, HL60 and S180. IC50 values of the compound represented by the general formula (I) in inhibiting the proliferations of the four tumor cells are calculated. As a result of experiments, with the compound represented by the general formula (I), proliferations of tumor cells can be substantially inhibited. The compound has excellent anti-tumor activity, and can be prepared into anti-tumor medicines.

The invention provides a plastic composition and a plastic surface metallizing method. The plastic composition contains plastic matrix resin and metal chelate; the metal chelate is a complex of metal ions and organic chelating agent; and the organic chelating agent is at least one of diketone, aminocarboxylic acid, thiocarboxylic acid, polycarboxylic acid and nitrogen-containing heterocyclic compound with a general formula CnH8N2, wherein n is 10, 12 or 14. The plastic surface metallizing method comprises the following steps of: performing injection molding on the plastic composition provided by the invention to form a plastic piece, then performing laser etching on the plastic piece by adopting laser with wavelength of 1,064 nanometers to 1,000 microns, and chemically plating a laser etching area to form a metal plating layer. The organic chelating agent adopted in the plastic composition has low cost and is sensitive to the laser, so the plastic surface has high activation degree; and when the plastic surface is metallized, the infrared laser with lower cost is adopted so that the metal ions of the metal chelate in the plastic piece are decomposed as an active center of subsequent chemical plating and the precision is very high.

A toner for forming a full color image, which includes a colorant and a binder resin including a polyester resin which is prepared by a polycondensation ester reaction in the presence of a titanium-containing catalyst selected from the group consisting of halogenated titanium, titanium diketone enolates, titanium carboxylates, titanyl carboxylates, and salts of titanyl carboxylates. A toner kit including a yellow toner, a magenta toner, a cyan toner and a black toner, wherein each of the toners is the toner mentioned above. An image forming apparatus including an image bearing member; a charger; a light irradiator; a developing device configured to develop an electrostatic latent image with a developer including the toner mentioned above; a transfer device; and a fixing device.

The invention relates to a powdered composite calcium zinc stabilizing agent and a preparation method thereof and belongs to the preparation of a stabilizing agent for plastic processing. The stabilizing agent consists of the following components in percentage by weight: 14 to 38 percent of poly-fatty acid resin calcium zinc, 20 to 45 percent of epoxy fatty acid calcium zinc soap, 10 to 15 percent of phosphite ester, 10 to 15 percent of beta-diketone compound, 11 to 23 percent of hindered phenol antioxidant and 10 to 15 percent of lubricant. The preparation method comprises the following steps of: throwing a poly-fatty acid resin, a hydroxide of an alkali-earth metal, an oxide of zinc, high alcohol and oleic acid according to proportion into a reactor to perform salifying reaction to obtain the poly-fatty acid resin calcium zinc; performing epoxidation of the oleic acid, hydrogen peroxide and glacial acetic acid serving as raw materials in the presence of concentrated sulfuric acid serving as a catalyst according to the proportion to generate epoxy fatty acid, directly reacting the epoxy fatty acid with calcium hydroxide to obtain the high-purity epoxy fatty acid calcium soap; and compounding the poly-fatty acid resin calcium zinc with the epoxy fatty acid calcium soap reasonably and then adding other auxiliary agents to obtain the stabilizing agent. The powdered composite calcium zinc stabilizing agent and the preparation method thereof can effectively solve the problems of low compatibility and low dyeing property at an initial stage of the conventional polyvinyl chloride (PVC) calcium zinc stabilizing agent.

The invention discloses RGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones, which are three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD tetrapeptide and are shown in the general formula I. In the general formula I, R represents Arg-Gly-Asp-Val, Arg-Gly-Asp-Phe or Arg-Gly-Asp-Ser. The invention also discloses heterocyclic nucleuses of the novel conjugates, wherein R represents OH. The invention also discloses a preparation method and in-vitro anti-platelet aggregation effects of the novel conjugates, and also discloses an antithrombotic use of the novel conjugates in a rat thrombus formation model. A result shows that the three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD tetrapeptide (wherein R represents Arg-Gly-Asp-Val, Arg-Gly-Asp-Phe or Arg-Gly-Asp-Ser) and their heterocyclic nucleuses (wherein R represents OH) have good antithrombotic activity and clear application prospects in antithrombotic agent preparation.

As a novel substance having a novel skeleton, a novel organometallic complex that can emit phosphorescence in the green to red wavelength region and has high emission efficiency and a high yield of synthesis is provided. One embodiment of the present invention is an organometallic complex in which a diketone having a five-membered or six-membered alicyclic structure composed of carbon and hydrogen is a ligand.

In the formula, L represents a bidentate aromatic ligand and has at least a bond between carbon of an aromatic ring in the aromatic ligand and Ir. X represents a five-membered or six-membered alicycle composed of carbon and hydrogen. Further, R¹ represents a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms.

The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides novel 1,4-benzodiazepine-2,5-dione compounds, and methods of using novel 1,4-benzodiazepine-2,5-dione compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like.

Compositions and methods for determining the presence or concentration of glucose in a sample which may also contain an alpha-hydroxy acid or a beta-diketone. The method uses a compound having at least two recognition elements for glucose, oriented such that the interaction between the compound and glucose is more stable than the interaction between the compound and the alpha-hydroxy acid or beta-diketone, such that the presence of the alpha-hydroxy acid or the beta-diketone does not substantially interfere with said determination.